arctiin has been researched along with bortezomib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Kim, C; Lee, J; Lee, JH; Sethi, G; Um, JY | 1 |
1 other study(ies) available for arctiin and bortezomib
| Article | Year |
|---|---|
Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Arctium; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Furans; Glucosides; Humans; Multiple Myeloma; Phosphorylation; Plant Extracts; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Signal Transduction; STAT3 Transcription Factor; Tyrosine | 2019 |